scholarly journals Outcomes of direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis

2021 ◽  
Vol 6.1 (1) ◽  
pp. 46-53
Author(s):  
Doaa Bakr ◽  
Ibrahim Hassan ◽  
Elsayed Abd-Elmaksood ◽  
Ashraf Omar ◽  
Mahmoud Awad
Keyword(s):  
Liver Cirrhosis ◽  
Antiviral Therapy ◽  
Hcv Infection ◽  
Decompensated Liver Cirrhosis ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Non-invasive methods for the diagnosis of liver fibrosis in chronic HCV-infection

2021 ◽  
Vol 13 (1) ◽  
pp. 58-65
Author(s):  
A. I. Fazul’zyanova ◽  
A. K. Husainova ◽  
S. V. Tkacheva ◽  
F. M. Yakupova
Keyword(s):  
Liver Cirrhosis ◽  
Liver Fibrosis ◽  
Antiviral Therapy ◽  
Prognostic Significance ◽  
Hcv Infection ◽  
Direct Acting Antiviral ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Direct Acting ◽  
Severe Fibrosis

Objective: to study the values of fibrosis indices and transient elastometry in patients with chronic HCV infection who received antiviral therapy.Materials and methods: The study included 64 patients with chronic HCV infection who received antiviral therapy with direct-acting antiviral drugs or a combination of peginterferon and ribavirin.The fibrosis indices AAR, APRI and FIB-4 were calculated before the start of therapy and 6 months after its completion. Values of AAR>1, APRI≥1,5, and FIB-4≥1,45 were considered indicators of severe fibrosis. We studied the dynamics of fibrosis indices and elastometry values depending on the treatment regimen, their correlation and the prognostic significance of fibrosis indices in relation to elastometry.Results. Among patients treated with direct-acting antiviral drugs, a sustained virologic response was achieved in 100%, and peginterferon-containing regimen – in 85%. Elastometry and APRI and FIB-4 indices decreased in both groups. In patients without liver cirrhosis, the average elastometry after treatment decreased from 9,5±1,7 kPa to 6,7 ± 1.4 kPa (p = 0,0006). In patients with liver cirrhosis, the median of elastometry decreased from 20 to 11,7 kPa (p = 0,0006), the median of APRI decreased from 2,09 to 0,61 (p = 0,005), FIB-4 from 3,95 up to 2,22 (p = 0,022). The prognostic significance of FIB-4 in relation to elastometry before treatment was 81%, after – 82%.Conclusion. Successful etiotropic therapy leads to an improvement in values of liver fibrosis indices and transient elastometry in patients with HCV infection, including liver cirrhosis, regardless of the treatment regimen. The FIB-4 index showed the highest sensitivity and prognostic significance in determining severe fibrosis.

Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment

2017 ◽  
Vol 63 (2) ◽  
pp. 486-492 ◽  
Author(s):  
Justin Chan ◽  
Neliswa Gogela ◽  
Hui Zheng ◽  
Sara Lammert ◽  
Tokunbo Ajayi ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Liver Stiffness ◽  
Post Treatment ◽  
Hcv Infection ◽  
Direct Acting Antiviral ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Direct Acting

Real life results of direct acting antiviral therapy for HCV infection in HIV–HCV-coinfected patients: Epi-Ter2 study

AIDS Care ◽  
2019 ◽  
Vol 32 (6) ◽  
pp. 762-769 ◽  
Author(s):  
A. Piekarska ◽  
E. Jabłonowska ◽  
A. Garlicki ◽  
M. Sitko ◽  
W. Mazur ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Real Life ◽  
Hcv Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting

Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis

2019 ◽  
Vol 31 (1) ◽  
pp. 53-58 ◽  
Author(s):  
Mohamed Essa ◽  
Aliaa Sabry ◽  
Eman Abdelsameea ◽  
El-Sayed Tharwa ◽  
Mohsen Salama
Keyword(s):  
Liver Cirrhosis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Drugs ◽  
Decompensated Liver Cirrhosis ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”

2019 ◽  
Vol 2019 ◽  
pp. 1-1
Author(s):  
Armando Calogero ◽  
Evangelista Sagnelli ◽  
Massimiliano Creta ◽  
Silvia Angeletti ◽  
Gaia Peluso ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Renal Allograft ◽  
Hcv Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting

HCV GT1b-patient with alanine aminotransferase elevation and sustained virologic response achieved by grazoprevir/elbasvir discontinuation

2021 ◽  
Author(s):  
Hiroshi Takahashi ◽  
Tatsuo Kanda ◽  
Naoki Matsumoto ◽  
Taku Mizutani ◽  
Tomohiro Kaneko ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Alanine Aminotransferase ◽  
Sustained Virologic Response ◽  
Nonstructural Protein ◽  
Present Report ◽  
Virologic Response ◽  
Hcv Infection ◽  
Short Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

In the present Japanese female patient with alanine aminotransferase (ALT) elevation greater than 500 IU/l during combination therapy with grazoprevir/elbasvir against HCV infection, this therapy was stopped at week 8. However, sustained virologic response was achieved. In the present report, we also focused on ALT elevation and sustained virologic response during and after antiviral therapies. The current case report demonstrates that careful monitoring of liver function tests may be required during direct-acting antiviral therapy against HCV infection because it is now possible to treat patients with polypharmacy, patients with chronic kidney disease, patients with cirrhosis or aged patients. Careful attention should be paid to liver damage as one of the adverse events in the use of HCV nonstructural protein 3/4A protease inhibitors. Of interest, many publications have addressed both ALT elevations during direct-acting antiviral therapy and viral clearance in relatively short treatment durations.

scholarly journals Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?

IDCases ◽  
2018 ◽  
Vol 14 ◽  
pp. e00450 ◽  
Author(s):  
Cátia Dias ◽  
Filipa Duarte-Ribeiro ◽  
Sara Pipa ◽  
Ana Rita Barbosa ◽  
Margarida Mota ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Antiviral Therapy ◽  
Hcv Infection ◽  
Direct Acting Antiviral ◽  
Real Risk ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Direct Acting

Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection

2019 ◽  
Vol 26 (3) ◽  
pp. 362-372 ◽  
Author(s):  
Jacinta A. Holmes ◽  
Charles Carlton-Smith ◽  
Arthur Y. Kim ◽  
Emily O. Dumas ◽  
Joelle Brown ◽  
...  
Keyword(s):  
Immune Responses ◽  
Antiviral Therapy ◽  
Innate Immune ◽  
Hcv Infection ◽  
Innate Immune Responses ◽  
Dynamic Changes ◽  
Direct Acting Antiviral ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document